Edoxaban

CAT: 0804-HY-10264-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-10264-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research[1].
CAS Number
[480449-70-5]
Product Name Alternative
DU-176
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Factor Xa; Thrombin
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/edoxaban.html
Purity
99.81
Solubility
DMSO : 10 mg/mL (ultrasonic)
Smiles
O=C(N(C)C)[C@@H](CC1)C[C@H]([C@H]1NC(C(NC(C=C2)=NC=C2Cl)=O)=O)NC(C3=NC(CC4)=C(CN4C)S3)=O
Molecular Formula
C24H30ClN7O4S
Molecular Weight
548.06
Precautions
H302, H315, H319, H335
References & Citations
[1]Furugohri T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008 Sep;6 (9) :1542-9.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Authorea. 2023 Apr 17.|Elife. 2022 Mar 23:11:e77444.|J Thromb Haemost. 2025 Jun;23 (6) :1938-1952.|LabMed. 2024 Nov 18.|Molecules. 2023 Feb 28;28 (5) :2254.|Thromb Res. 2021 Jan:197:141-143.|Virology. 2023 Aug:585:205-214.|PLoS One. 2024 May 15;19 (5) :e0292628.

Related Products

CatalogName

Alternative Products

CatalogName
M16544-01Edoxaban
TRC-E555522-5MGEdoxaban-d6
M14605-01Edoxaban (b)
M14606-01Edoxaban tosylate
TRC-E480890-100MG(4S)-Edoxaban
T19873-01Edoxaban M4

Popular Products